Synergy of Iron Chelators and Therapeutic Peptide Sequences Delivered via a Magnetic Nanocarrier
Source abstract
Abstract
Here, we report the synthesis, characterization, and efficacy study of Fe/Fe3O4-nanoparticles that were co-labeled with a tumor-homing and membrane-disrupting oligopeptide and the iron-chelator Dp44mT, which belongs to the group of the thiosemicarbazones. Dp44mT and the peptide sequence PLFAERL(D[KLAKLAKKLAKLAK])CGKRK were tethered to the surface of Fe/Fe3O4 core/shell nanoparticles by utilizing dopamine-anchors. The 26-mer contains two important sequences, which are the tumor targeting peptide CGKRK, and D[KLAKLAK]2, known to disrupt the mitochondrial cell walls and to initiate programmed cell death (apoptosis). It is noteworthy that Fe/Fe3O4 nanoparticles can also be used for MRI imaging purposes in live mammals. In a first step of this endeavor, the efficacy of this nanoplatform has been tested on the highly metastatic 4T1 breast cancer cell line. At the optimal ratio of PLFAERD[KLAKLAK]2CGKRK to Dp44mT of 1 to 3.2 at the surface of the dopamine-coated Fe/Fe3O4-nanocarrier, the IC50 value after 24 h of incubation was found to be 2.2 times lower for murine breast cancer cells (4T1) than for a murine fibroblast cell line used as control. Based on these encouraging results, the reported approach has the potential of leading to a new generation of nanoplatforms for cancer treatment with considerably enhanced selectivity towards tumor cells.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Chemical Synthesis and Analysis · Peptidase Inhibition and Analysis · Nanocluster Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, Kansas State University, Manhattan, KS 66041, USA
tbs3@ksu.edu (T.B.S.)
Microscopy and Analytical Imaging Laboratory, University of Kansas, Lawrence, KS 66045, USA
Funding
National Science Foundation · Johnson Cancer Center
References (26)
Show source-provided references
1. Cancer Statistics, 201710.3322/caac.21387 ↗
2. Design of a Tumor-Homing Cell-Penetrating Peptide10.1021/bc0701139 ↗
3. Potent Retro-Inverso d-Peptide for Simultaneous Targeting of Angiogenic Blood Vasculature and Tumor Cells10.1021/bc300537z ↗
4. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?10.1016/j.jconrel.2016.11.015 ↗
5. Bossmann, S.H., and Wang, H. (2017). Magnetic Nanoformulations for Enhanced Drug Delivery and Retention. Magnetic Nanomaterials: Applications in Catalysis and Life Sciences, The Royal Society of Chemistry.
6. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma10.1073/pnas.1114518108 ↗
7. Anti-cancer activity of targeted pro-apoptotic peptides10.1038/12469 ↗
8. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma10.1016/S1535-6108(03)00273-3 ↗
9. The Iron Chelator Dp44mT Causes DNA Damage and Selective Inhibition of Topoisomerase IIα in Breast Cancer Cells10.1158/0008-5472.CAN-08-1437 ↗
10. The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study10.1016/j.jinorgbio.2010.07.012 ↗
11. The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells10.1016/j.bbamcr.2016.09.011 ↗
12. Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2α, IRE1α, ATF6 and calmodulin kinase10.1016/j.bcp.2016.04.001 ↗
13. Enhanced targeting of mitochondrial peroxide defense by the combined use of thiosemicarbazones and inhibitors of thioredoxin reductase10.1016/j.freeradbiomed.2015.12.008 ↗
14. Determination of Peptide Substrate Specificity for μ-Calpain by a Peptide Library-based Approach: the importance of primed side interactions10.1074/jbc.M506870200 ↗
15. Attenuation of Mouse Melanoma by A/C Magnetic Field after Delivery of Bi-Magnetic Nanoparticles by Neural Progenitor Cells10.1021/nn100870z ↗
16. Balivada, S., Rachakatla, R.S., Wang, H., Samarakoon, T.N., Dani, R.K., Pyle, M., Kroh, F.O., Walker, B., Leaym, X., and Koper, O.B. (2010). A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: A mouse study. BMC Cancer, 10.10.1186/1471-2407-10-119 ↗
17. Magnetic-Fe/Fe3O4-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages10.3762/bjnano.3.51 ↗
18. Nanoplatforms for highly sensitive fluorescence detection of cancer-related proteases10.1039/c3pp50260k ↗
19. Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection10.3762/bjnano.7.33 ↗
20. Redox cycling metals: Pedaling their roles in metabolism and their use in the development of novel therapeutics10.1016/j.bbamcr.2016.01.026 ↗
21. Iron and cancer: recent insights10.1111/nyas.13008 ↗
22. Dopamine as A Robust Anchor to Immobilize Functional Molecules on the Iron Oxide Shell of Magnetic Nanoparticles10.1021/ja0464802 ↗
23. Nanoparticles in magnetic resonance imaging: From simple to dual contrast agents
24. Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity10.1039/c2dt12387h ↗
25. Peptide Coupling Reagents, More than a Letter Soup10.1021/cr100048w ↗
26. Sitaampalam, G.S. (2004). Assay Guidance Manual.